HER2-positive gastroesophageal junction adenocarcinoma
Clinical trials for HER2-positive gastroesophageal junction adenocarcinoma explained in plain language.
Never miss a new study
Get alerted when new HER2-positive gastroesophageal junction adenocarcinoma trials appear
Sign up with your email to follow new studies for HER2-positive gastroesophageal junction adenocarcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trio takes aim at HER2-Positive stomach cancer
Disease control Recruiting nowResearchers are comparing a new combination of disitamab vedotin, sintilimab, and S-1 against the standard regimen of trastuzumab plus chemotherapy, with or without sintilimab, for people with advanced HER2-positive gastric or gastroesophageal junction cancer. The trial enrolls a…
Matched conditions: HER2-POSITIVE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase 2 • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can an antibody boost chemotherapy to stop early stomach cancer from returning?
Disease control Recruiting nowThis trial is testing whether adding the targeted antibody trastuzumab to standard chemotherapy after surgery can help prevent early-stage (IB-II) HER2-positive gastric cancer from coming back. About 120 adults who have had their tumor removed will be randomly assigned to receive…
Matched conditions: HER2-POSITIVE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase 2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a targeted cancer drug deliver in the real world?
Disease control Recruiting nowThis observational study is tracking 260 adults in China with HER2-positive gastric or gastroesophageal junction cancer that is locally advanced or has spread. Participants are receiving trastuzumab deruxtecan (T-DXd) as part of their routine care, and researchers are collecting …
Matched conditions: HER2-POSITIVE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Cancer drug enhertu gets a shot in the arm: new Under-the-Skin version tested
Disease control Recruiting nowThis early-phase trial is testing a new way to give the cancer drug T-DXd (Enhertu) — as a shot under the skin instead of an IV drip. The study will enroll 76 adults with metastatic solid tumors to find the safest dose and see how well the body handles it. Researchers will also c…
Matched conditions: HER2-POSITIVE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase 1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC